Cmp Dev Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CMP DEV LLC, and what generic alternatives to CMP DEV LLC drugs are available?
CMP DEV LLC has six approved drugs.
There are twenty US patents protecting CMP DEV LLC drugs.
There are sixteen patent family members on CMP DEV LLC drugs in nine countries and fifty-two supplementary protection certificates in eleven countries.
Drugs and US Patents for Cmp Dev Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | 11,369,567 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,660,907 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,888,570 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,624,906 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cmp Dev Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2018397436 | ⤷ Try a Trial |
Brazil | 112020012986 | ⤷ Try a Trial |
Morocco | 43132 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2019130052 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cmp Dev Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0443983 | C300445 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016 |
0740668 | 03C0017 | France | ⤷ Try a Trial | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
2101777 | CA 2016 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125 |
0463756 | 99C0007 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.